Ligand id: 10013

Name: AbGn-168H

Immunopharmacology Comments
In addition to blocking the PSGL-1/P-selectin pathway that is involved in leukocyte recruitment to inflammatory sites, AbGn-168H also induces T cell and NK cell depletion/apoptosis. This novel mechanism of action has the potential to control pathologic T cell- or NK cell-mediated immune responses in autoimmune diseases, transplant rejection, allergic diseases and T cell cancer.
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
Phase 2 clinical evaluation of AbGn-168H in patients with moderate to severe chronic plaque psoriasis (NCT01855880) and active psoriatic arthritis (NCT02267642) has been completed, but results have not yet been published (July 2018).